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Abstract 
The usage of recombinant human erythropoietin in clinics to treat cancer-associated anemia has 
shown unfortunate unforeseen tumour response to cytokine treatment. Although other cytokines 
have previously been shown to have an effect on p53-dependent tumourigenesis and apoptosis in 
vitro, the effects of erythropoietin on cancer development have only recently been observed in 
vivo, of which a potential mechanism has yet to be elucidated. To determine the potential 
mechanism by which erythropoietin mediates the evasion of apoptosis in cells, we used the wild-
type p53-expressing murine leukemic cell line DA3-EPOR and induced apoptosis via 
daunorubicin and doxorubicin treatment. Our findings suggest that EPO rescues cells from p53-
dependent apoptosis and enhances proteasomal degradation of p53 with a concomitant decrease 
in miR-34a, miR-34b/c, and lincRNA-p21 expression. EPO was also observed to increase p53 
recruitment to the p21 promoter followed by increased p21 expression, suggesting an 
orchestrated shift from p53-dependent apoptosis to cell cycle arrest. 
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1. Introduction 
The evasion of apoptosis through the manipulation and circumvention of normal cellular 
processes is regarded as a hallmark of cancer (Hanahan and Weinberg 2000). The progression of 
tumourigenesis and acquisition of cancer hallmarks are typically associated with accumulation of 
mutations that have escaped DNA repair mechanisms. In some cases, tumours have also been 
found capable of utilizing factors present in their microenvironment, such as cytokines, to 
promote their own survival (Dranoff 2004). Erythropoietin (EPO), an erythropoiesis-stimulating 
cytokine, has recently been observed to promote the survival of tumours, which was discovered 
following EPO treatment of patients with cancer-associated anemia (Henke et al. 2003; Leyland-
Jones 2003). We decided to take a p53 perspective in examining the mechanism by which EPO 
aids cancers in evading apoptosis. This is due to the well-established role of p53 in regulating 
apoptosis (Fridman and Lowe 2003) and the basis in which other cytokines have been found to 
affect p53-dependent apoptosis (Dranoff 2004). This introduction will focus on summarizing the 
role and interconnections between cancer-associated anemia, EPO, apoptosis, and p53. 
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1.1 Erythropoietin 
1.1.1 Cancer-associated anemia and EPO 
Anemia is a condition denoted as a decrease in red blood cell (RBC) volume and can be 
associated with the manifestation of numerous different types of illnesses, including but not 
limited to renal failure, dysfunctional erythropoiesis in the bone marrow, iron deficiency, sickle 
cell disease, and cancer (Steinberg 1989).  In cancers, the origin of anemia tends to be difficult to 
diagnose as it may arise from both the cancer itself as well as the chosen cancer therapies. 
Cancer-associated anemia can result from impairment in RBC production caused by 
chemotherapy, hematopoietic cancers, blood loss-inducing cancers, advanced metastatic cancers, 
and/or vascular tumours among many other factors (Steinberg 1989). Although the causes of 
cancer-associated anemia may vary it is generally agreed upon that anemia in patients may 
greatly influence their quality of life and prognosis. In a comprehensive review of the MEDLINE 
database, Caro et al. found that in the 60 articles surveyed, there was a 20-43% reduction in 
median survival for cancer patients diagnosed as anemic compared with non-anemic patients 
across a large variety of cancer types (2001).  As such, treatment of anemia in cancer patients is 
imperative as it has been shown to increase overall survival and quality of life (Steinberg 1989). 
To this end, anemic cancer patients are typically treated with recombinant human erythropoietin 
(rhEPO) or erythropoietin-stimulating agents (ESAs). These treatments utilize the EPO pathway 
to bolster normal erythropoiesis in the body and reduce the need for blood transfusions (Szenajch 
et al. 2010).  
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1.1.2 Erythropoiesis and EPO’s signalling pathway 
EPO treatment utilizes the normal erythropoiesis pathway in the body to stimulate RBC 
production and offset cancer-associated anemia. Normally erythropoiesis is stimulated in the 
body under hypoxic or anemic conditions, where a decrease in blood volume or blood oxygen 
levels upregulates the expression of EPO’s primary transcription factor hypoxia-inducible factor 
2 (HIF-2). HIF-2 then subsequently stimulates the production of EPO by the kidney. In the fetus 
however, EPO is produced from the liver and is later produced primarily in the kidney as an 
adult, although it can still be produced minutely in the adult liver (Kapitsinou et al. 2010).  
EPO is released into the bloodstream where it travels until it reaches cells expressing an 
EPO-receptor (EPOR). EPORs are normally found on the cell surface of erythroid progenitors in 
the bone marrow and are lost upon differentiation into mature RBCs. To a lesser extent, EPORs 
have also been found expressed in the brain, heart, and kidney tissues, and are believed to have a 
tissue protective effect (Chateauvieux et al. 2011; Jelkmann et al. 2010). Binding of EPO to an 
EPOR on erythroid progenitors in the bone marrow causes dimerization of the EPOR molecules 
which then triggers a conformational change in the receptors’ extracellular domain. EPOR does 
not have intrinsic kinase activity of its own and downstream signalling from EPOR depends on 
the activation of pre-associated Janus kinase 2 (JAK2). The conformational change in EPOR 
activates pre-associated JAK2 via an auto-phosphorylation event. Activated JAK2 then 
phosphorylates tyrosine domains on the cytoplasmic region of EPOR (Witthuhn et al. 1993). 
This phosphorylation event recruits various Src homology-2 domain-containing (SH2) 
downstream effectors to the activated EPOR homodimer. A few of the effectors recruited include 
members of the signal transducer and activator of transcription (STAT) family, 
phosphatidylinositol-3 kinase (PI3K) and subsequently protein kinase B (PKB), and the adaptor 
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protein growth factor receptor-bound protein 2 (Grb2) which activates the RAS/RAF pathway 
(Bouscary et al. 2003; Constantinescu et al. Haq et al. 2002; Socolovsky et al. 2001). Activation 
of these downstream effectors leads to upregulation of various regulated genes, such as B-cell 
lymphoma-extra-large (Bcl-xL), and downregulation of other genes including caspase-3 
(Gregory et al. 1999; Zermati et al. 2001). As result, the EPOR pathway promotes the survival 
and differentiation of erythroid progenitors into mature RBCs (Ghezzi and Brines 2004; Iwatsuki 
et al. 1997) (Figure 1). The usage of rhEPO and ESAs has since become an essential component 
to the treatment regimen of cancer patients suffering from anemia. 
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Figure 1: EPOR signalling pathway in erythroid progenitor cells. 1) Erythropoietin binds to 
its EPO-receptor causing dimerization. 2) Dimerization of EPOR bring pre-associated JAK2 into 
closer proximity with each other, leading to auto-phosphorylation of JAK2. 3) JAK2 then 
phosphorylates tyrosine residues on the cytoplasmic domain of EPOR. 4) SH2-domain 
containing downstream effectors, such as PI3K, Grb2, and the STAT family, are recruited to 
EPORs’ phosphorylated tyrosines. 5) Downstream signalling of the PI3K, Grb2/RAS/RAF, and 
STAT pathways results in promotion of survival and differentiation of erythroid progenitors into 
mature red blood cells.  
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1.1.3 EPO and cancer 
In 2003 the first documented cases of an in vivo tumour response to EPO treatment were 
observed, resulting in significant changes to how EPO was to be prescribed to anemic cancer 
patients in future. In The Breast Cancer Erythropoietin Trial (BEST), a higher mortality rate was 
found in patient groups treated with chemotherapy and epoietin, a rhEPO, compared with groups 
treated only with chemotherapy (Leyland-Jones 2003). Similarly, patients pre-treated with 
epoietin in the Erythropoietin in Head and Neck Cancer trial (ENHANCE) along with radiation 
therapy to prevent cancer-associated anemia fared worse than patients who were not pre-treated 
(Henke et al. 2003). There have also been a number of reports linking usage of ESAs in 
conjunction with radiation therapy being especially detrimental to patients’ overall survival 
(Machtay et al. 2007; Shenouda et al. 2015). EPOR expression in cancers has since been linked 
to aggressive tumour behaviour, risk of thromboembolism, increased angiogenesis in cancers, 
and drug resistance, raising concerns about EPO’s continued usage in cancer-associated anemia 
treatment (Farrell and Lee 2004; Lin et al. 2012; Zhang et al. 2012).  
However there is still a lack of consensus on whether EPOR expression is present and 
functional in many cancers, with some studies reporting cancers expressing a non-functional 
EPOR or having no response to EPO treatment despite functional EPOR expression (Radwan et 
al. 2016; Senger et al. 2016; Bennet et al. 2016). There have also been a number of clinical trials 
that have found no difference in overall survival between cancer patients treated with ESAs 
compared with control groups (Aapro et al. 2008; Crawford et al. 2007; Grote et al. 2005). In 
response to the reports indicating a potential detrimental effect of ESA and rhEPO treatment of 
cancer-associated anemia in patients, many professional organizations have issued revised 
guidelines to clinicians on how to evaluate when cancer-associated anemia can be treated with 
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EPO. These guidelines emphasize a full risk-assessment of the necessity of palliative EPO 
treatment for only chemotherapy-treated cancer patients in addition to continued evaluation of 
patient haemoglobin levels in case of potential tumour response (Rizzo et al. 2010).  
 Despite the conflicting results on the role of EPO in cancer treatment, it remains clear 
that EPOR’s role in cancer development and progression is still uncertain and more research is 
required to further elucidate how some cancers may be utilizing the EPOR pathway. Studies 
have since mainly focused on the following: new methods to detect EPOR expression and 
function, observing for EPO-induced phenotypic changes in conjunction with drug treatments 
and delineating a possible mechanism if a change is observed, clinical studies observing for 
effects of EPO treatment, and determining relative expression and function of EPOR in cancers 
(Fuge et al. 2015; Jin et al. 2015; Maxwell et al. 2015; Park et al. 2014). 
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1.2 P53 
1.2.1 p53 and cancer 
P53 is a tumour suppressor whose importance in guarding against tumourigenesis is undisputed. 
There are three main lines of evidence that support p53’s classification as a tumour suppressor 
gene: frequent loss of p53 function through mutation in cancers, germline p53 mutations present 
in families with Li-Fraumeni Syndrome, and susceptibility of p53-null mice to tumour 
development. Somatic p53 mutations occur in a large majority of cancers, with prevalence of 
over 40%  in 8 out of 29 cancer types covered by the datasets from the IARC TP53 Database and 
TCGA/ICGC Database as of 2016 (Bouaoun et al. 2016). In cancers with a low rate of p53 
mutation, wild-type p53 (WTp53) expression can be circumvented via increased degradation 
(Kubbutat et al. 1997). Inherited germline p53 mutations, characterized as Li-Fraumeni 
Syndrome, predispose their carriers to a higher risk of cancer development (Li and Fraumeni 
1969). Homozygous p53 null mice are highly susceptible to tumour development, with tumours 
developing on average within 45 weeks with 100% penetrance (Donehower 1996). The 
propensity in which mice and humans expressing mutated p53 develop tumours owes in part to 
p53’s function as a transcription factor of genes associated with cell cycle arrest, senescence, and 
apoptosis. Correspondingly, p53 mutations are most commonly missense mutations located 
within the DNA-binding domain of p53, resulting in an inability of p53 to bind to DNA and 
function as a transcription factor (Petitjean et al. 2007). 
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1.2.2 p53 function as a transcription factor 
P53 is capable of suppressing tumour development primarily through its function as a mediator 
of cell response to stress signals. Normally p53 protein is maintained at low levels in the cell 
through ubiquitylation by E3 ubiquitin ligases which mark p53 for proteasomal degradation 
(Kubbutat et al. 1997; Rodriguez et al. 2000). In response to cell stresses, such as DNA damage, 
nutrient starvation, telomere erosion, and hypoxia, p53 undergoes significant post-translational 
modifications leading to its stabilization. Stabilized p53 proteins form a tetramer and bind to 
promoters at a p53 response element (p53RE) sequence of PuPuPuC(A/T)(A/T)GPyPyPy 
N{0,13} PuPuPuC(A/T)(A/T)GPyPyPy. Binding of p53 to target gene promoters stimulates 
transcription through recruitment of transcriptional activators (El-Deiry et al. 1992). Depending 
on the degree and type of stress, p53 is preferentially recruited to promoters of genes associated 
with apoptosis or cell cycle arrest. Upregulation of p53 target genes thus activates downstream 
pathways that allow for prevention/repair of damaged cells during cell cycle arrest or removal of 
damaged cells via apoptosis. P53’s stabilization and function as a transcription factor has been 
summarized in brief in Figure 2. 
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Figure 2: P53’s function as a transcription factor. P53 protein is maintained at low steady-
state levels via constant protein degradation. In response to stress signals, p53 undergoes post-
translational modification which leads to its stabilization and tetramerization. Stabilized p53 is 
recruited to promoters of apoptotic and cell cycle arrest targets containing a p53 consensus 
sequence. Binding of p53 results in upregulation of transcription and activation of downstream 
pathways associated with cell cycle arrest or apoptosis.  
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1.2.3 p53 stabilization, activation, and promoter recruitment 
P53 undergoes many post-translational modifications (PTMs) in response to stress stimuli, 
leading to its stabilization and activation (Kruse and Gu 2009). Some post-translational 
modifications that have been found associated with p53 include acetylation, sumoylation, 
phosphorylation, neddylation, and methylation. Different stresses result in different 
modifications to p53 and allow for the preferential recruitment of p53 to promoters of genes 
involved in apoptosis and cell cycle arrest (Meek and Anderson 2009).  
 A large component of the stabilization of p53 involves the uncoupling of the association 
between p53 and E3 ubiquitin ligases which target p53 for degradation. One of the most 
extensively studied PTM pathways involved in this process are the ataxia telangiectasia mutated-
checkpoint kinase 2 (ATM-Chk2) and ataxia telangiectasia-and RAD3-related-checkpoint kinase 
1 (ATR-Chk1) pathways which respond to doubled stranded and single stranded DNA breaks 
respectively. Upon DNA damage, ATM and/or ATR phosphorylate mouse double minute 
homolog-2 (MDM2), an E3 ubiquitin ligase that targets p53, at various serine and threonine 
residues located near its C-terminal domain (CTD). Phosphorylation of these sites on MDM2 
results in inhibition of MDM2 and its ability to ubiquitinate p53. ATM and ATR also 
phosphorylate Chk2 and Chk1 respectively, which in turn phosphorylate residues on p53 that 
help to retain it in the nucleus and contribute to disassociation of p53 from MDM2 (Smith et al. 
2010). Additionally, p14
ARF
, an inhibitor that binds to MDM2 and blocks its ubiquitin ligase 
function, is frequently mutated in cancers and is one of the mechanisms by which cancers 
circumvent WTp53 expression (Bates et al. 1998). 
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PTMs and cofactors associated with p53 work in concert to not only activate and stabilize 
p53, but to facilitate its recruitment to promoters. Phosphorylation of p53 by ATM/ATR has 
been found to serve as a nucleation event that promotes the recruitment of histone/lysine 
acetyltransferases, such as p300 and CREB-binding protein (CBP), to p53. Acetylation of p53, 
particularly at its CTD, is believed to help stabilize p53 by blocking ubiquitylation of the CTD 
and contribute to uncoupling p53 from MDM2 (Meek and Anderson 2009; Sakaguchi et al. 
1998). These modifications are also thought to contribute to p53 association with response 
elements on target genes. Tip60, also known as histone acetyltransferase KAT5, has been shown 
to acetylate p53 at K120, which is essential for p53-dependent apoptosis but is dispensable for 
cell cycle arrest (Tang et al. 2006). Methylation of p53 by methyltransferase Set7/9 was also 
found to mediate the acetylation of p53 by Tip60, however methylation was not required for p53-
mediated cell cycle arrest and apoptosis (Campaner et al. 2011; Kurash et al. 2007). These PTM 
interactions represent only a few of numerous cofactors and modifications that act on p53, but 
display the intricacy in which p53 is regulated. Analysis of p53 modifications via mass 
spectrometry revealed over 150 possible PTMs present on p53, suggesting that the PTMs that 
govern p53 stability, activation, and promoter recruitment are very complex (DeHart et al. 2013). 
Cofactors and PTMs that act on p53 not only aid in its recruitment to promoters but also 
act on the promoters themselves to help upregulate gene transcription. P53-mediated recruitment 
of histone acetyltransferases p300/CBP and Tip60 serve to acetylate histones within the vicinity 
of p53REs, which relaxes chromatin structure and allows for active transcription to occur. P53 is 
also capable of recruiting components of the pre-initiation complex (PIC) to the promoter of 
target genes, allowing for initiation of transcription (Beckerman and Prives 2010). Altogether 
this highlights the complexity of p53’s function as a transcription factor and the network of 
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PTMs and cofactors involved in its stabilization, activation, and recruitment to promoters (Figure 
2). 
1.2.4 p53 degradation 
Under normal conditions p53 protein is maintained at low levels via constant degradation and 
only upregulated upon cell stress. In cancers, enhanced WTp53 degradation via ubiquitylation 
and proteasomal degradation may allow for circumvention of WTp53 and subsequent 
progression in tumourigenesis. Considering p53’s role in regulating cell cycle arrest and 
apoptosis in response to stress, post-translational modifications associated with p53 that govern 
its stability and degradation are highly important to suppressing tumourigenesis. 
The most characterized interaction involved in the control of p53 degradation is its 
ubiquitylation by E3 ubiquitin ligases. Ubiquitylation involves the conjugation of ubiquitin to a 
protein. Depending upon the degree of ubiquitylation, proteins can be marked for proteasomal 
degradation (poly-ubiquitylated) or nuclear export (mono-ubiquitylated), amongst other protein 
fates (Lohrum et al. 2001; Rodriguez et al. 2000). MDM2 is the first and most well-known E3 
ubiquitin ligase discovered to target p53 (Kubbutat et al. 1997).  Since MDM2’s discovery, 
several other E3 ligases have been reported, including but not limited to mouse double minute 4 
homology (MDM4) and p53-induced RING-H2 domain protein (Pirh2) (Chao 2015; Leng et al. 
2003). MDM2 is capable of binding to p53 and ubiquitylating lysines K370, K372, K373, K381, 
K382, and K386 located at p53’s CTD (Lohrum et al. 2001).  Poly-ubiquitylation of these sites 
marks p53 for degradation by the proteasome. Notably it was observed that a p53 mutant 
expressing Lysine to Arginine mutations at the 6 targeted lysines (p53-6KR) showed no increase 
in stability, suggesting that although important for degradation, the ubiquitination of these 
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lysines may not be essential for p53 degradation (Feng et al. 2005). MDM2 is also 
transcriptionally regulated by p53, resulting in a negative feedback loop. This auto-regulatory 
loop allows for upregulated p53 levels to return to homeostatic levels after a stress response (Wu 
et al. 1993).  
There has been interest in developing drugs that target interactions involved with WTp53 
degradation in cancers, allowing for rescue of WTp53 expression. Two such drugs are 
proteasomal inhibitors and E3 ubiquitin ligase inhibitors like MG-132 and nutlin-3 respectively. 
MG-132 is a proteasomal inhibitor which targets the 20S proteasome subunit, whereas nutlin-3 is 
a cis-imidazoline analog which inhibits the interaction between MDM2 and p53, thus stabilizing 
p53 (Guo and Peng 2013; Vassilev et al. 2004). 
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1.2.5 p53 and its coding and non-coding RNA network 
Since its discovery, the p53 network has expanded extensively to include genes not only 
associated with apoptosis and cell cycle arrest, but implicated also in metabolism, angiogenesis, 
and fertility. A large number of p53 target genes however, are involved in cell cycle arrest (ex. 
p21, B-cell translocation gene 2 (BTG2)) and apoptosis (ex. p53 upregulated modulator of 
apoptosis (PUMA), Noxa, p53-induced protein with a death domain (PIDD)) (Vogelstein et al. 
2000). P53’s transcriptional activation of p21 in particular, a cyclin-dependent kinase (CDK) 
inhibitor, is a well-known target involved in the p53-dependent mediation of G1-arrest. P21 
inhibits the activity of cyclin-CDK complexes cyclin-CDK1, cyclin-CDK2, and cyclin-CDK4/6 
and allows for regulation of cell cycle progression (Abbas and Dutta 2009). BTG2 has also been 
found to contribute to arrest at the G1-S checkpoint via inhibition of cyclin D1 transcription 
(Guardavaccaro et al. 2000). In terms of apoptotic genes, PUMA and Noxa are both Bcl-2 
homology domain (BH3)-only protein family members and indirectly inhibit Bcl-2 family 
members Bax and/or Bak to promote mitochondrial membrane permeabilization and 
consequently apoptosis (Ploner et al. 2008; Yu and Zhang 2008). PIDD’s role by contrast, still 
remains elusive, but has been implicated with activation of caspase-2 (Bock et al. 2012). 
In addition to the numerous coding RNA targets that p53 regulates, a number of non-coding 
RNAs (ncRNAs) have been recognized as being part of the p53 network. NcRNAs are capable of 
regulating gene expression but do not code for a specific protein (Acunzo et al. 2015). 
MicroRNAs (miRNA) are a small class of ncRNAs (~22nt) that have differential effects on gene 
regulation through imperfect binding to a complementary sequence located in the 3’UTR of a 
target mRNA. This typically results in the inhibition of translation or degradation of the mRNA 
target. In 2007, multiple groups independently identified members of the microRNA-34 (miR-
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34) family as being regulated by p53. MiR-34a in particular has been found to have differential 
context-dependent effects when overexpressed, ranging from cell cycle arrest to apoptosis 
(Bommer et al. 2007; Chang et al. 2007; He et al. 2007; Raver-shapira et al. 2007; Tarasov et al. 
2007). MiR-34b/c, another member of the miR-34 family, shares similar target mRNAs with 
miR-34a and has also been implicated with cell cycle arrest, apoptosis, and metabolism (Corney 
et al. 2007). Deregulated expression of miRNA is frequently reported in cancer, resulting in an 
interest in determining the role of miRNAs in tumorigenesis (Acunzo et al. 2015). P53 has also 
been found to regulate the expression of long intergenic ncRNAs (lincRNAs), which are >200 
nucleotides in length and are also implicated in the regulation of gene expression. In 2010 
lincRNA-p21 was discovered and found to be located 15kb upstream of the p21 gene. Reports on 
lincRNA-p21’s function however, have been mixed, with studies showing conflicting reports on 
lincRNA-p21’s function involving either apoptosis or cell cycle arrest (Dimitrova et al. 2014).  
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1.2.6 p53, cytokines, and apoptosis 
Apoptosis is governed by the complex integration of both survival and death signals. Growth 
signals such as EPO promote the evasion of apoptosis in part by coordinating the upregulation of 
survival signals (Dranoff 2004). Considering EPO has been found to aid cancer cells in evasion 
of apoptosis when treated with chemotherapeutic drugs, our lab focused on studying the possible 
intersection between EPOR signal transduction and p53-dependent apoptosis. Previously our lab 
has found that EPO is capable of rescuing DP16.1/p53ts cells from p53-dependent apoptosis with 
a shift towards G1-arrest and a concomitant increase in p21 levels. DP16.1/p53ts cells express a 
temperature-sensitive p53 (p53ts) mutant that adopts a mutant conformation at 37°C but wild-
type (WT) conformation at 32°C. These cells also express the spleen focus-forming virus-
encoded env-related glycoprotein gp55 that is capable of binding and activating EPOR, thus 
mimicking the natural EPO/EPOR signalling pathway (Brown and Benchimol 2006; Johnson 
and Benchimol 1992; Lin et al. 2002). Quelle et al. reported similar findings in WTp53 
expressing 32D and DA3-EPOR cells, with EPO showing capability of rescuing cells from 
apoptosis after gamma-irradiation which required JAK2 but not PI3K activation (1998).  
Similar to EPO, other cytokines such as the interleukin (IL) family and macrophage inhibitor 
factor (MIF) have also been found to have a role in rescuing cells from p53-dependent apoptosis. 
Interleukins are cytokines produced by leukocytes and are involved in regulation of immune 
responses. IL-6 treatment has been connected to enhanced p53 protein degradation by MDM2 
via increased ribosomal RNA transcription which reduced the availability of ribosome proteins 
for MDM2 binding (Brighenti et al. 2014). IL-7 was also observed to decrease p53-dependent 
apoptosis in A549 and human bronchial epithelial cells through upregulation of Bcl-2 and 
downregulation of Bax expression (Liu et al. 2014). Decreased p53 expression and inhibition of 
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apoptosis has also been observed in irradiated B lymphoma cells in the presence of IL-17 (Li et 
al. 2015). MIF treatment was also observed to suppress p53 binding to p53-responsive luciferase 
promoters, overcome p53-mediated apoptosis and cell cycle arrest induced by doxorubicin (Dox) 
and estradiol respectively, and decrease p53 protein levels (Brock et al. 2014; Hudson et al. 
1999).  These findings represent only a few of the many reports linking cytokines with the 
inhibition of p53-dependent apoptosis, and underscore the importance of understanding the 
contribution of survival signalling to the evasion of apoptosis in cancers. 
  
19 
 
1.3 Thesis rationale 
The current work focuses on further examining EPO’s ability to rescue cancer cells from stress-
induced apoptosis in the DA3-EPOR cell line and its effects on the p53 network. DA3-EPOR is a 
WT p53 expressing murine leukemic cell line expressing EPOR obtained from Dwayne Barber 
at the Princess Margaret Hospital and serves as an appropriate system to observe EPO’s 
involvement with WT p53 in a more physiological context (Miura et al. 1991). Although much 
work has been done to elucidate the mechanism of EPO enhancement of tumourigenesis, there 
exists little in the literature connecting EPO to p53-dependent apoptosis. Other cytokines have 
been examined more extensively in terms of their roles associated with p53-dependent apoptosis 
and may serve as support to there being a potential connection between EPO and the p53 
network. The objective of this research project was determine if EPO is capable of rescuing cells 
from p53-dependent apoptosis induced by daunorubicin (DNR) and doxorubicin (DOX) in the 
more physiologically-relevant DA3-EPOR system via a p53-dependent pathway. Further 
observations on EPO’s effect on the p53 network and p53 itself may serve to elucidate the 
mechanism by which WTp53 leukemic cells evade apoptosis in the presence of EPO.   
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2. Materials and methods  
2.1 Cell culture  
DA3-EPOR murine leukemic cells were maintained at 37°C with 5% CO2 in RPMI 1640 media 
supplemented with 10% fetal bovine serum (FBS) and 1 U/mL recombinant human 
erythropoietin (EPO).  DA3-EPOR/p53DD cells were established via nucleofection of DA3-
EPOR cells with a pCMV vector containing p53DD, kindly provided by Dr. Moshe Oren. For 
treatment, cells were washed with RPMI 1640 with 10% FBS and incubated at 37°C for one hour 
without EPO. Cells are then either treated with 0.25 µM DNR, 0.25 µM Dox, and/or 1 U/mL 
recombinant human EPO. Cell viability was assessed routinely via exclusion of trypan blue. For 
inhibitor treatments, MG-132 (Sigma-Aldrich Canada Ltd., Toronto, ON, Canada) and 
cycloheximide (Sigma-Aldrich Canada Ltd., Toronto, ON, Canada) were added directly to 
culture media and harvested at appropriate timepoints. 
2.2 Nucleofection 
Nucleofection of DA3-EPOR cells were performed according to the instructions provided by the 
manufacturer (Lonza). 2x10
6 
DA3-EPOR cells were resuspended in Cell Line Nucleofector 
Solution V and combined with 2 µg of plasmid vector comprised of a 9:1 ratio of pCMV/p53DD 
plasmid (Bowman et al. 1996) to pSUPER-puromycin. Cells were then pulsed with the 
Nucleofector X-001 program using a Nucleofector 2b device kindly provided by Dr. Peter 
Cheung. Pulsed cells were transferred to pre-warmed RPMI1640 media containing 10% FBS and 
1 U/mL EPO and allowed to recover for 48 hrs. 19 clones were then isolated for puromycin 
selection over 4 weeks (1 µg/mL, Sigma-Aldrich Canada Ltd., Toronto, ON, Canada). Clones 
were subjected to immunoblotting and flow cytometry to validate for p53DD expression after 4 
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weeks. Clones #16, 18, and 19 were selected for continued experimentation due to their high 
expression of p53DD. 
2.3 Cell cycle analysis 
Cells were pelleted and washed with PBS and fixed in cold 70% ethanol before freezing at -20°C 
until use. Fixed cells were washed with PBS at room temperature and resuspended in Staining 
Buffer (0.2% Triton X-100, 1 mM EDTA, in PBS) followed by incubation with 50 µg/mL 
RNaseA (ThermoScientific) at 37°C for 30 minutes. Cells were then stained with 50 µg/mL 
propidium iodide per treatment for one hour. Propidium iodide fluorescence was measured using 
a BD FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) and data analysis 
was performed using the BD CellQuest Pro software. 
2.4 Western blotting 
Cells were directly lysed in 1X SDS lysis buffer (10% SDS, 10% glycerol, 88 mM Tris-HCl pH 
6.8, in water) and boiled at 97°C for 10 minutes followed by addition of 0.1% bromophenol blue 
and 0.1M DTT. Cell lysates were re-boiled and allowed to cool before loading onto SDS-
polyacrylamide gels and subjected to electrophoresis. Gels were transferred onto nitrocellulose 
membranes and incubated with the appropriate antibodies. The following primary antibodies 
were used in this study: p21 (Santa Cruz Biotechnology, Santa Cruz, CA), PAb421 which 
recognizes the c-terminal domain of p53 (Harlow et al. 1981), FL393 (Santa Cruz 
Biotechnology, Santa Cruz, CA), and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA). 
Protein quantification was measured using a Typhoon Trio scanner (GE Healthcare). The 
following secondary antibodies were used in this study for protein quantification using a 
phosphoimager: murine and rabbit anti-Cy 3 and anti-Cy5. Protein loading was assessed using 
Coomassie blue staining of polyacrylamide gels after transfer and β-actin quantification.   
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2.5 Cycloheximide treatment 
After treatment of cells with DNR and/or EPO, 40 µg/mL cycloheximide (Sigma-Aldrich) was 
added directly to culture media. Cells were harvested at 0 minutes, 30 minutes, 60 minutes, 120 
minutes, and 240 minutes after cycloheximide addition and subjected to immunoblotting. 
Relative p53 and β-actin protein expression was quantified using a Typhoon Trio (GE 
Healthcare) and ImageJ software. Relative p53 expression was normalized to β-actin levels and 
plotted relative to initial p53 levels at 0 minutes after cycloheximide addition for each individual 
treatment. 
2.6 Quantitative Real-Time PCR 
Template RNA was prepared from treated cells using TRIzol Reagent (Life Technologies) and 
synthesized into cDNA according to the manufacturer’s instructions using the High Capacity 
RNA-to-cDNA Kit (ThermoFischer Scientific).  
Template RNA was mixed with RNAse/DNase-free water and RevoScript RT Premix 
tubes and subjected to cDNA synthesis using an Applied Biosystems GeneAmp PCR System 
9700 (ThermoFischer Scientific). cDNA synthesis was performed at 50°C for 60 minutes and 
RTase inactivation at 95°C for 5 minutes. Prepared cDNA was stored at -20°C until use and 0.5 
µM of cDNA was used per qRT-PCR reaction. SsoFaster EvaGreen Supermix Kits and an 
Applied Biosystems 7500 Real-Time PCR System (ThermoFischer Scientific) were used 
according to the manufacturer’s instructions. Obtained Ct values were normalized to the 
endogenous control 18S using the Pfaffl method (Pfaffl 2001). qRT-PCR products were 
validated via northern blots for appropriate product size (data not shown).  
Primer efficiencies were evaluated and calculated prior to use in qRT-PCR. The 
following oligonucleotides were used as qRT-PCR primers: Pri-miR-34a (He et al. 2007), F 5’ 
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CTG TGC CCT CTT GCA AAA GG 3’, R 5’ GGA CAT TCA GGT GAG GGT CTT G 3’; Pri-
miR-34b/c, F 5’ CTC GGT TTG TAG GCA GTG TA 3’, R 5’ TTG ATG GCA GTG GAG TTA 
GTG 3’; lincRNA-p21, F 5’ CAT TCC GTC TCC AGT TCC TAA C 3’, R 5’ CGA AGA GAC 
AAC GGC ACA CTT 3’; PIDD, F 5’ TCC AGC AAG ATG TGA GCT TAT G 3’, R 5’ GGT 
CAT TCC AGG TGT TGT TAC T 3’; PUMA, F 5’ CGG AGA CAA GAA CC AGC AAG ATG 
TGA GCT TAT G 3’, R 5’ GGT CAT TCC AGG TGT TGT TAC T 3; NOXA, F 5’ TCG CAA 
AAG AGC AGG ATG AG 3’, R 5’ CAC TTT GTC TCC AAT CCT CCG 3’; p21, F 5’ CCA 
GAC ATT CAG AGC CAC AGG 3’, R CGA AGA GAC AAC GGC ACA CTT 3’; p53, F 5’ 
TAG GTA GCG ACT ACA GTT AGG G 3’, R 5’ CAT GGC AGT CAT CCA GTC TT 3’; 18S, 
F 5’ GTG TTG AGG AAA GCA GAC AT 3’, R 5’ CAG TCT GGG ATC TTG TAC TG 3’. 
2.7 ChIP-qPCR 
Treated cells were cross-linked through addition of formaldehyde to a final concentration of 1% 
and incubated at room temperature for 8 minutes, followed by addition of 0.125 M glycine for 5 
minutes at room temperature. Cells were pelleted at 1200 RPM at 4°C for 8 minutes and washed 
with ice cold Phosphate-Buffered Saline 1X (Corning), followed by washes with Wash Buffer I 
(0.25% Triton X-100, 10 mM EDTA pH 8.0, 0.5 mM EGTA pH 7.5, 10 mM Hepes pH 7.5, 
protease inhibitor cocktail tablet (Roche)) and Wash Buffer II (12.5 mM NaCl, 1 mM EDTA pH 
8.0, 0.5 mM EGTA pH 7.5, 10 mM Hepes, protease inhibitor cocktail tablet), and resuspension 
in Lysis buffer (0.15 M NaCl, 25 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 1% Triton X-100, 0.1% 
SDS, 0.5% Sodium deoxycholate, protease inhibitor cocktail tablet) respectively. Resuspended 
cells were sonicated to a size between 100-400bp using a Sonic Dismembrator Model 500 
(ThermoFischer Scientific) kindly provided by Dr. Robert Tsushima. Sonicated cells were then 
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centrifuged at 14000 RPM at 4°C to pellet cell debris. Cell lysates were pre-cleared with pre-
washed Protein-A agarose beads (Bioshop Canada Inc.) for 1 hour at 4°C.  
1 mg of protein from pre-cleared cell lysates were then incubated with 2 µg of either 
FL393 or IgG antibody at 4°C overnight. 40 µg of protein from pre-cleared cell lysates were set 
aside for use as input. Cell lysates were incubated with 40 µL of prewashed Protein-A agarose 
beads for 1 hour at 4°C and then pelleted at 4000 RPM for 5 minutes at 4°C. Protein-Agarose 
bead complexes were washed with RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 
0.5% Sodium deoxycholate, 1% NP-40, protease inhibitor cocktail), High Salt buffer (0.5 M 
NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 1% NP-40, protease inhibitor cocktail), LiCl buffer (0.25 
M LiCl, 50 mM Tris pH 8.0, 0.5% Sodium deoxycholate, 1% NP-40, protease inhibitor cocktail), 
and TE buffer (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0, protease inhibitor cocktail). Washed 
beads were then incubated with IP elution buffer (2% SDS, 10 mM DTT, 0.1 M NaHCO3) for 30 
minutes at room temperature. Eluted protein complexes were collected and boiled at 65°C 
overnight after addition of 20 µL of 4 M NaCl to reverse crosslinks. 
1 µL of 10 mg/mL RNAseA was added to each sample and incubated at 37°C for 30 
minutes. 20 µL of 10X proteinase K buffer (0.1 M Tris-HCl pH 8.0, 0.05 M EDTA pH 8.0) and 
20 µL of 20 mg/mL proteinase K was added to each reaction and incubated at 42°C for 1 hour. 
DNA was then separated from each reaction via phenol-chloroform extraction followed by 
precipitation via incubation at -80°C with 1/10
 
reaction volume of 3 M NaOAC pH 5.2, 2X 
reaction volume of cold 95% ethanol, and 1 µL of glycogen per reaction. Samples were pelleted 
at 14000 RPM for 15 minutes at 4°C and DNA pellets were washed with 80% ethanol and stored 
in RNAse/DNAse free water at -80°C until use.   
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ChIP DNA samples were subjected to quantitative real-time PCR using SsoFaster 
EvaGreen Supermix Kits and an Applied Biosystems 7500 Real-Time PCR System 
(ThermoFischer Scientific) according to the manufacturer’s instructions. Obtained Ct values 
were normalized to non-IP input samples for each treatment and expressed as enrichment 
compared with input (%input). Primer efficiencies were evaluated and calculated prior to use in 
ChIP-qPCR.  
The following oligonucleotides were used as ChIP-qPCR primers: miR-34a, F 5’ CCA 
CTT TTT CTT CCC AGG TG 3’, R 5’ CCC CAA TCT GTG CAG TTA CC 3’; miR-34b/c (He 
et al. 2007), F 5’ GTT GAT CCT GCC CAC AGT TAC TAG A 3’, R 5’ ATT AAA ACA TGA 
GTC TCC CTG GTC TCT 3’; p21, F 5’ ACC AGC AGC AAA ATC GGA GC 3’, R 5’ CCC 
ACA GCT GGT AGT TGG GTA TC 3’. 
2.8 Data analysis 
Statistics were performed using Microsoft Excel and SPSS software. 
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3. Results 
3.1 EPO rescues DA3-EPOR cells from DNR and Dox-induced apoptosis 
Previously the Benchimol Lab has observed that EPO is capable of rescuing DP16.1/p53ts cells 
from p53-dependent apoptosis (Lin et al. 2002). To determine whether EPO is also capable of 
rescuing cancer cells from apoptosis in a more physiological system, DA3-EPOR cells were 
treated with DNR, Dox, with or without EPO for 16 hours and assessed by flow cytometry after 
PI staining. Apoptotic cells appear as a population of cells with < 2 N DNA content (sub-G1 
population). Under normal conditions, DA3-EPOR cells are cultured in media containing EPO 
and display low Sub-G1 population levels of 3.56% (Figure 3). Under genotoxic stress, cells 
treated with Dox or DNR displayed an increase in Sub-G1 population levels of 38.76% and 
67.46% respectively (Figure 3). In the presence of EPO, cells showed a significant decrease in 
Sub-G1 population levels despite Dox (p=0.0050) and DNR treatment (p=0.0025). Sub-G1 
population levels of Dox and DNR treated cells in the presence of EPO compared with Dox and 
DNR treatments alone were decreased by -0.90 and -0.89 fold respectively (Figure 3A). 
Representative cell cycle profiles from one replicate in Figure 3A can be observed in Figure 3B. 
These data suggest that EPO’s ability to rescue cells from apoptosis is not restricted to 
DP16.1/p53ts cells. For the following experiments we chose to focus on DNR treatment as the 
Sub-G1 population levels and EPO rescue observed for DNR treatment was more robust, and 
served as a more appropriate system to further investigate the mechanism of EPO rescue. 
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Figure 3: EPO rescues DA3-EPOR cells from Dox and DNR induced apoptosis.  A) Cells 
were starved of EPO for 1hr followed by 16hrs of treatment with Dox (0.25µM), DNR (0.25 
µM), and/or EPO (1 U/mL). Treated cells were fixed with 70% ethanol and then subjected to 
propidium iodide staining and flow cytometry. Error bars represent SEM (N=3 biological 
replicates) and p-values were obtained via Student’s two-tailed t-test. B) Representative of cell 
cycle profiles after DNR, Dox, and EPO treatment. Contributed by Weili Ma and Thuc-Nghi 
Pham.  
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3.2 EPO rescues DA3-EPOR cells from p53-dependent apoptosis 
Although it has been previously shown that EPO is capable of rescuing DP16.1/p53ts cells from 
p53-dependent apoptosis, we wanted to determine if DNR-induced cell death was also dependent 
on p53 in DA3-EPOR cells. To this end, DA3-EPOR clones that express p53DD, a dominant 
double-negative truncated p53, were generated via nucleofection to determine whether DNR-
induced apoptosis is p53-dependent. 19 DA3-EPOR/p53DD clones were generated in total, of 
which clones 16, 18, and 19 were chosen for continued use due to their high expression of 
p53DD (Figure 4). DA3-EPOR/p53DD clones showed an overall significant decrease in Sub-G1 
population levels, with percent apoptotic cells ranging from 26.85-29.60% for each p53DD 
clone,compared with DA3-EPOR cells when treated with DNR for 16 hours (p<0.0001) (Figure 
5), suggesting that DNR treatment induces p53-dependent apoptosis in DA3-EPOR cells. 
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Figure 4: DA3-EPOR cells nucleofected with pCMV/p53DD vector express p53DD. DA3-
EPOR cells were co-nucleofected with pCMV/p53DD and pSUPER-puromycin vectors and 19 
clones were selected after puromycin selection over four weeks. Clones 16, 18, and 19 displayed 
the strongest expression of p53DD. Cells were harvested under normal culturing conditions 
containing EPO (1 U/mL) and subjected to immunoblotting. 
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Figure 5: DA3-EPOR/p53DD clones show a reduction in sub-G1 population levels 
compared with DA3-EPOR cells when treated with DNR. DA3-EPOR cells were co-
nucleofected with a pCMV/p53DD and pSUPER-puromycin vector and clones # 16, 18, and 19 
were selected out of a total 19 clones after puromycin selection over four weeks. Cells were 
starved of EPO for 1hr followed by 16hrs of treatment with DNR (0.25 µM) and/or EPO (1 
U/mL). Treated cells were fixed with 70% ethanol and then subjected to propidium iodide 
staining combined with flow cytometry. Error bars represent SEM and p-values were calculated 
through one-way ANOVA analysis followed by Tukey’s HSD posthoc test (N=3).  
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3.3 EPO decreases p53 protein stability via the proteasomal pathway but does not affect 
p53 mRNA stability 
In our investigation of EPO’s effect on the p53 pathway, we observed that p53 protein levels 
decrease with EPO and DNR treatment compared with DNR treatment alone (Figure 6). The 
decrease in p53 protein levels also appeared to be much more pronounced with the usage of 
monoclonal antibody PAb421, which recognizes the C-terminal domain of p53, compared with 
polyclonal FL393 (Figure 6). There was also an observed decrease in p53 mRNA with DNR 
treatment for 6 hours, but no considerable change in the presence of EPO (Figure 7). Considering 
this, we decided to investigate if EPO’s effect on p53 protein levels was associated with changes 
in p53 protein stability via an analysis of p53 protein levels after treatment and addition of 
cycloheximide, an inhibitor of protein translation, in DA3-EPOR cells. As expected, p53 protein 
levels were stabilized upon DNR treatment and showed only a 20.6% decrease in protein levels 
after 4 hours of CHX treatment (Figure 8). In the presence of EPO and DNR however, p53 
protein levels show a 75.7% decrease in relative expression after 4 hours of CHX treatment 
compared with initial levels (Figure 8). No change in p53 protein level was observed in cells 
treated with DMSO-vehicle control. These novel data indicate that EPO destabilizes p53 protein 
in DNR-treated cells.  
 The proteasomal pathway is arguably one of the most well-known pathways involved in 
the degradation of proteins. As such, through using MG-132, an inhibitor that binds to the 20S 
proteasomal subunit thus blocking proteasomal degradation, we sought out to determine if p53 
protein stability could be rescued from EPO treatment in the presence of MG-132. MG-132 
treatment of DA3-EPOR cells treated with DNR and EPO rescues p53 protein expression 
compared with cells treated without MG-132 (Figure 9). Together, these findings suggest that 
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EPO may affect p53 protein stability through the proteasomal degradation pathway in DNR-
treated cells. To our knowledge, this is the first instance of EPO being reported to decrease p53 
protein stability via a proteasomal degradation pathway. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: EPO treatment decreases p53 protein level in the presence of 6hr DNR treatment 
in DA3-EPOR cells. Cells were starved of EPO for 1hr followed by 6hrs of treatment with DNR 
(0.25 µM) and/or EPO (1 U/mL). Treated cells were harvested and subjected to immunoblotting. 
Contributed by Weili Ma. 
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Figure 7: EPO treatment does not affect p53 mRNA levels in DA3-EPOR cells. Cells were 
starved of EPO for 1hr followed by 6hrs of treatment with DNR (0.25 µM) and/or EPO (1 
U/mL). RNA was harvested from treated cells and 0.5µM of cDNA was used per qRT-PCR 
reaction. Obtained Ct values were normalized to the endogenous control 18S using the Pfaffl 
method. Error bars represent SEM (N=3 biological replicates). Contributed by Weili Ma. 
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Figure 8: EPO decreases p53 protein stability in DA3-EPOR cells. Cells were starved of EPO 
for 1hr followed by 6hrs of treatment with DNR (0.25 µM) and/or EPO (1 U/mL). A) 
Cycloheximide (40 µg/mL) was added after 6hrs of treatment with DNR and/or EPO. Treated 
cells were harvested at the given time points after cycloheximide addition and subjected to 
immunoblotting. The data shown is representative of two independent experiments. B) Relative 
p53 proteins levels were quantified using ImageJ and normalized to β-actin levels. Normalized 
p53 protein levels were then plotted as a relative value compared with normalized p53 protein 
levels at 0min after cycloheximide addition (N=2). 
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Figure 9: EPO promotes proteasomal degradation of p53 in DA3-EPOR cells. Cells were 
starved of EPO for 1hr followed by 6hrs of treatment with DNR (0.25 µM) with or without EPO 
(1 U/mL). After 6hrs of treatment, MG-132 (5 µM) was added for an additional 4hrs and 
harvested cells were subjected to immunoblotting (N=1). 
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3.4 EPO modulates the RNA expression of some p53 target genes 
Upon genotoxic stress in cells, p53 undergoes substantial post-translational modifications which 
result in its recruitment to and subsequent upregulation of target genes involved in cell cycle 
arrest and apoptosis. Considering the observed effect of EPO on both p53-dependent apoptosis 
and p53 protein stability in DA3-EPOR cells, we next assessed EPO’s potential effect on the 
expression of p53 target genes via qRT-PCR. EPO was observed to have an enhancing effect on 
p21 mRNA expression at 4 hours of treatment with EPO and DNR compared with DNR alone 
(Figure 10A and Figure 10B), but was only observed as significant in Figure 10A. An increase in 
p21 protein levels with EPO treatment was also confirmed via immunoblotting (data not shown). 
By contrast, EPO significantly decreased the expression of non-coding RNAs pri-miR-34a, pri-
miR-34b/c, and pri-lincRNA-p21 (Figure 10C-F). Under DNR treatment alone, pri-miR-34a, pri-
miR-34b/c, and pri-lincRNA-p21 RNA levels are enhanced significantly after 12 hours, but are 
significantly decreased in the presence of EPO (Figure 10D-E). However, we did not observe 
any significant changes in the mRNA expression at any timepoints of treatment for PIDD, 
PUMA, or Noxa (Figure 11).  Together these findings suggest that EPO significantly modulates 
the expression of some but not all p53 target genes.  
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Figure 10: EPO with DOX and/or DNR treatment modulates the RNA expression of p53 
target genes A/B) p21, C/D) miR-34a,  E) miR-34b/c, and F) lincRNA-p21 in DA3-EPOR 
cells. Cells were starved of EPO for 1hr followed by treatment with Dox (0.25 µM), DNR (0.25 
µM), and/or EPO (1 U/mL) for the given timepoints. RNA was harvested from treated cells and 
0.5 µM of cDNA was used per qRT-PCR reaction. Obtained Ct values were normalized to the 
endogenous control 18S using the Pfaffl method. Error bars represent SEM (N=3 biological 
replicates) and p-values were obtained via one-way ANOVA analysis followed by Tukey’s HSD 
post hoc test. Contributed by Weili Ma, David Miller, Yael Spiegel, and Thuc-Nghi Pham. 
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Figure 11: EPO with Dox and/or DNR treatment does not modulate the mRNA expression 
of p53 target genes A) PIDD, B) PUMA, and C) Noxa in DA3-EPOR cells. Cells were 
starved of EPO for 1hr followed by treatment with Dox (0.25 µM), DNR (0.25 µM), and/or EPO 
(1 U/mL) for the given timepoints. RNA was harvested from treated cells and 0.5µM of cDNA 
was used per qRT-PCR reaction. Obtained Ct values were normalized to the endogenous control 
18S using the Pfaffl method. Error bars represent SEM (N=3 biological replicates) and p-values 
were obtained via one-way ANOVA analysis followed by Tukey’s HSD post hoc test. 
Contributed by Weili Ma, David Miller, and Thuc-Nghi Pham. 
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3.5 EPO enhances p53 recruitment to the p21 promoter 
To determine if EPO modulates p53-target gene expression through changes in the recruitment 
of p53 to target gene promoters, we assessed the recruitment of p53 to the p21, miR-34a, and 
miR-34b/c promoters under different treatments via ChIP-qPCR. Compared with DNR treatment 
alone, we observed a significant increase in p53 recruitment to the p21 promoter in the presence 
of EPO after 16 hours of treatment (Figure 12A). P53 recruitment to the p21 promoter was also 
observed under EPO treatment alone and with EPO withdrawal, suggesting that p53 may be 
present at the p21 promoter under normal conditions in the absence of genotoxic stress (Figure 
12A). Unfortunately we were unable to determine any significant changes in p53 recruitment to 
the miR-34a and miR-34b/c promoters due to signal levels falling below or on par with IgG 
background levels (Figure 12B and Figure 12C). Together these findings suggest that EPO 
enhances p53 recruitment to the p21 promoter. Further experimentation is required to determine 
EPO’s effect on p53 recruitment to the miR-34a and miR-34b/c promoters. 
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Figure 12: EPO treatment enhances p53 recruitment to the p21 promoter in DA3-EPOR 
cells. Quantitative PCR analysis of ChIPs performed against p53 at the A) p21 and B) miR-34a 
and C) miR-34 b/c promoters after EPO and DNR treatment. DA3-EPOR cells were starved of 
EPO for 1hr followed by 16hrs of treatment with DNR (0.25 uM) and/or EPO (1 U/mL). 
Obtained Ct values were normalized to non-IP input and p53 levels for each sample and are 
expressed as Enrichment (% /input).  Error bars represent standard error of the mean (N=3 
biological replicates) and p-values were obtained from one-way ANOVA followed by Tukey’s 
HSD post hoc test. 
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4. Discussion 
Our findings help to elucidate the mechanism by which EPO rescues DA3-EPOR cells from p53-
dependent apoptosis in addition to underlying effects on p53 and the p53 network. The 
possibility that EPO decreases p53 protein stability via a proteasomal pathway has not been 
reported to our knowledge. This is particularly exciting considering the majority of blood-borne 
cancers that express EPOR retain WTp53 expression (Canman et al. 1995; Petitjean et al.2007). 
Although previous work on EPO’s involvement with p53-dependent apoptosis has helped to 
further our understanding on the subject, there has mainly been a focus on downstream effectors 
of p53 or EPOR as opposed to p53 itself (Lin et al. 2002; Quelle et al. 1999). Another caveat of 
some of these papers are their utilization of a p53ts system, which despite allowing for 
determination of a p53-dependent response, may also result in non-physiological p53 levels of 
expression (Quelle et al. 1999). Quelle et al. also observed EPO rescue from p53-dependent 
apoptosis in irradiated DA3-EPOR cells, but unfortunately did not definitively show p53-
dependence or relative p53 protein expression (1999). As such, in this study we have focused on 
further investigating the effects of EPO on the p53 network and elucidating the mechanism by 
EPO rescues DA3-EPOR cells from DNR and Dox-induced apoptosis. 
4.1 EPO rescues DA3-EPOR cells from p53-dependent apoptosis 
In agreement with our previous findings in DP16.1/p53ts cells (Lin et al. 2002), we have found 
that EPO is also capable of rescuing DA3-EPOR cells from apoptosis triggered by DNR and Dox 
treatment. Unlike DP16.1/p53ts cells, DA3-EPOR cells represent a more physiological system 
that expresses EPOR and WTp53, and thus provide support to the idea that EPO may affect a 
larger scope of leukemic cancer systems. To determine if EPO rescues DA3-EPOR cells from 
p53-dependent apoptosis, we transfected DA3-EPOR cells with the dominant negative p53DD 
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fragment and observed for changes in cell cycle profiles after DNR treatment. DA3-
EPOR/p53DD cells showed a decrease in apoptotic cells with DNR treatment compared with 
DA3-EPOR cells, confirming that EPO rescues the cells from p53-dependent apoptosis. 
Considering p53’s role in apoptosis in DA3-EPOR cells, as well as their established role in 32D 
and DP16.1/p53ts cells (Lin et al. 2002; Quelle et al. 1999), it is likely that EPO’s involvement 
in the evasion of apoptosis in leukemic cell lines must somehow circumvent WTp53. 
4.2 EPO affects the stability of p53 protein but not mRNA 
In our efforts to further understand EPO’s effect on p53 we observed a decrease in p53 protein 
but not mRNA levels in the presence of DNR and EPO compared with DNR alone. To our 
knowledge, this has not been observed previously and suggests that EPO affects p53 protein 
levels. Interestingly, probing with the monoclonal antibody PAb421 showed a more substantial 
decrease in p53 levels compared with probing the same blot with polyclonal FL393. Considering 
PAb421 recognizes the C-terminal end of p53 this may suggest a decrease in availability of the 
c-terminal domain of p53 possibly results from PTMs or cofactor binding after EPO treatment 
(Poyurovsky et al. 2010). Another possibility could be due to the strength/affinity of PAb421 for 
p53, resulting in an overall weaker signal compared with FL393.  By comparison, we observed 
no change in p53 mRNA levels with EPO treatment, suggesting that EPO targets p53 at the 
protein level and not mRNA level. We did however, observe a decrease in p53 mRNA levels 
with DNR treatment. It is possible that severe DNA damage may have affected p53 mRNA 
transcription but not p53 protein translation or stabilization (Siemer et al. 1999). Regardless, the 
reason behind the observed p53 mRNA decrease with DNR treatment remains unclear. 
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4.3 EPO decreases p53 protein stability via the proteasomal pathway 
Considering EPO’s effect on p53 protein levels, we wanted to determine whether EPO was 
directly targeting p53 post-transcriptionally or post-translationally.  DA3-EPOR cells were 
treated with DNR and/or EPO followed by CHX treatment and imaged with immunoblotting to 
observe changes in p53 protein stability. We observed a decrease in p53 protein stability in the 
presence of DNR and EPO treatment compared with DNR alone, suggesting that EPO regulates 
p53 protein levels post-translationally. It has previously been shown that p53 is post-
translationally regulated via ubiquitination by MDM2, marking it for proteasomal degradation 
(Kubbutat et al. 1997; Rodriguez et al. 2000).  To determine whether EPO enhances p53 
degradation mediated by the proteasomal pathway, we treated EPO and/or DNR treated DA3-
EPOR cells with MG-132, a proteasomal inhibitor that binds to the 20S proteasome subunit (Guo 
and Peng 2013). We observed that MG-132 treatment was capable of rescuing p53 protein levels 
after EPO treatment, suggesting that EPO increases p53 association with the proteasome, leading 
to its degradation. This suggests that EPO may promote survival through enhanced degradation 
of p53. This is very exciting considering many blood-borne cancers still retain WTp53 status, 
and may serve as a potential mechanism for how these cancers may circumvent WTp53 
expression. EPO has also been previously observed to mediate the degradation of Bcl-2 
interacting mediator of death (BIM) via proteasomal degradation in erythroid cells, which 
supports the possibility that the EPO pathway may be connected to proteasomal degradation 
(Abutin et al. 2009). Future work utilising Nutlin-3, an inhibitor that abrogates the interaction 
between MDM2 and p53, may allow for further elucidation of the mechanism by which p53 is 
degraded in the presence of EPO (Vassilev et al. 2004). Together with the decrease in protein 
44 
 
levels of p53 mentioned earlier, this suggests that EPO acts on p53 post-translationally to 
decrease the expression of p53 via enhanced proteasomal degradation.  
4.4 EPO modulates the expression of some but not all p53-target genes 
Since we observed EPO’s effect on p53-dependent apoptosis and p53 protein levels, we next 
investigated potential downstream effects on the p53 network. Despite the decrease in p53 
protein levels observed, we only observed some modulation in expression of p53-target genes via 
qRT-PCR. This modulation included the ncRNAs miR-34a, miR-34b/c, lincRNA-p21 and 
coding RNA p21, but not coding RNAs PUMA, Noxa, and PIDD. It is unclear whether any of 
these changes are causally related to the pro-survival function of EPO. Although PUMA, Noxa, 
and PIDD mRNA levels did increase with DNR treatment as expected (Bock et al. 2012; Ploner 
et al. 2008; Yu and Zhang 2008), there was no significant change observed in the presence of 
EPO. It is possible that activation of pro-survival pathways by EPO may have circumvented any 
initiation of apoptosis by PUMA, Noxa, or PIDD. Further investigation into the protein 
expression of these genes and potential preservation of mitochondrial integrity may shed more 
light into their role in these cells.  
We also observed a decrease in expression for ncRNAs miR-34a, miR-34b/c, and lincRNA-
p21 with EPO treatment, in addition to inconclusive ChIP-qPCR results for p53 presence at the 
miR-34a and miR-34b/c promoters. MiR-34a, miR-34b/c, and lincRNA-p21 have previously 
been associated with p53-dependent apoptosis (Bommer et al. 2007; Chang et al. 2007; Corney 
et al. 2007; Dimitrova et al. 2014), but we were unable determine whether their decreased 
expression is essential for evasion of apoptosis or whether it is a result of decreased p53 
expression and recruitment to promoters. Due to the ability of ncRNAs to regulate transcription 
of multiple targets, the potential role for ncRNAs in EPO’s evasion of apoptosis is particularly 
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exciting (Acunzo et al. 2015). Future work determining potential changes in expression of 
downstream targets of these ncRNAs would provide more insight into their role in EPO rescue 
from p53-dependent apoptosis.  
An increase in p21 levels and increased p53 recruitment to the p21 promoter was observed in 
the presence of EPO and DNR compared with DNR alone, suggesting that EPO enhances p21 
expression via increased p53 recruitment to the p21 promoter. Considering EPO’s enhancement 
of p21 expression occurs concomitantly with decreased p53 expression, it is possible that p21 
expression may in part also be stimulated independent of p53. Another possibility is that EPO-
dependent changes in p53 PTMs, such as a loss of Tip60-mediated acetylation, results in 
preferential recruitment of p53 to the p21 promoter. This may explain the decrease in p53 levels 
yet increased p53 recruitment to the p21 promoter. Interestingly, there was also a decrease in p53 
recruitment to the promoter with DNR treatment as well as a small basal amount of p53 recruited 
the promoter under all conditions over IgG background. This is consistent with the idea that 
some p53 is found present on the p21 promoter in unstressed cells (Kaeser and Iggo 2002) and 
that DNR treatment may preferentially shift p53 recruitment to apoptotic target genes, resulting 
in a decrease in p53 recruitment to p21. There is also an increase in p53 recruitment to the p21 
promoter with EPO withdrawal, which may be the result of an EPO withdrawal stress that 
induces G1-arrest. These findings support our previous work suggesting that EPO is mediating 
survival of these cells from stress-induced apoptosis dependent on p53 by shifting the cells from 
apoptosis to G1-arrest (Lin et al. 2002).  
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4.5 Conclusions 
Altogether this work suggests and supports the concept that EPO rescues cells from p53-
dependent apoptosis caused by DNR/Dox treatment in addition to increased proteasomal 
degradation of p53 and an orchestrated shift from p53-dependent apoptosis to cell cycle arrest. 
EPO was also observed to have an effect on expression of p53 target genes, which included 
decrease in expression of ncRNAs in the p53 network but increase in p21 expression and 
recruitment of p53 to the p21 promoter (Figure 13). This work helps to broaden our 
understanding of EPO’s effect in cancer cells and potentially target the pathway by which 
cancers utilize EPO for apoptosis evasion.  
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Figure 13: Schematic of the effects of EPO on p53-dependent apoptosis and the p53 
network in DA3-EPOR cells. EPO rescues cells from p53-dependent apoptosis and enhances 
proteasomal degradation of p53 with a concomitant decrease in miR-34a, miR-34b/c, and 
lincRNA-p21 expression. EPO was also observed to increase p53 recruitment to the p21 
promoter followed by increased p21 expression. 
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5. Future directions 
Although we have observed a number of changes in the p53 network with EPO treatment, 
it is important to determine what factors are fundamental in EPO’s ability to rescue cancer cells 
from apoptosis. Future work would require delineating the mechanism of EPO’s rescue from 
apoptosis and dissecting where this may involve p53 and its network.  
5.1 Determination of factors involved in p53 degradation with EPO treatment 
We have observed increased p53 proteasomal degradation with EPO treatment, however it has 
yet to be determined what other factors may be involved in shuttling p53 protein towards the 
proteasome. Potentially, p53 is being ubiquitylated, leading to its recruitment to the proteasome. 
Utilization of Tandem Ubiquitin Binding Entity (TUBE) technology, which allows for the 
characterization and isolation of ubiquitylated proteins, may allow for identification of ubiquitin 
levels on p53 with EPO treatment (Hjerpe et al. 2009). If p53 is found to have elevated 
ubiquitylation with EPO treatment, it is likely that an E3 ubiquitin ligase is involved in its 
ubiquitylation. MDM2 has previously been established as the primary E3 ubiquitin ligase to 
target p53 in the literature (Kubbutat et al. 1997). To determine whether ubiquitylation of p53 
may be associated with MDM2, treatment of cells with Nutlin-3, an inhibitor of the interaction 
between MDM2 and p53, would elucidate whether MDM2 contributes to p53 degradation. Co-
immunoprecipitation of MDM2 bound to p53 would also help to determine if there is increased 
interaction between the two factors. However, if ubiquitylation of p53 proves to be MDM2-
independent, other E3 ubiquitin ligases, such as Pirh2, could be examined (Leng et al. 2003). 
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5.2 Determination of the importance of p53 degradation for EPO-induced G1 arrest and 
evasion of apoptosis  
It still remains unclear as to whether the enhanced degradation of p53 with EPO treatment is 
sufficient for evasion of apoptosis and subsequent induction of G1-arrest. Although p53DD 
clones showed reduced apoptotic cells with DNR treatment, this demonstrates the effect of p53 
inactivation as opposed to p53 knockdown in these cells. To determine if the partial knockdown 
of p53 protein levels by EPO treatment is sufficient for evasion of apoptosis, cells expressing 
short hairpin RNA (shRNA) constructs to partially knockdown p53 expression in the presence of 
only DNR treatment could be generated and evaluated for influence on cell cycle profile. The 
usage of multiple shRNA constructs with varied ability to reduce p53 levels has previously been 
used to evaluate the effects of differing levels of p53 expression on cell phenotype (Hemann et 
al. 2003). A similarly designed experiment in DA3-EPOR cells should determine the importance 
of partial p53 knockdown to EPO evasion of apoptosis. 
5.3 Mechanistic study of p53 recruitment to the p21 promoter 
Although we observed enhanced p53 degradation as a result of EPO treatment, it is unclear how 
there is also enhanced recruitment of p53 to the p21 promoter and an increase in p21 levels. It is 
possible that p53 is post-translationally modified and/or associated with cofactors in such a way 
that stable forms of p53 that are not actively degraded are preferentially recruited to the p21 
promoter. To determine whether post-translationally modified p53 and/or recruiters are present at 
the p21 promoter under EPO treatment, Global ExoNuclease-based Enrichment of Chromatin-
Associated Proteins for Proteomics (GENECAPP) may potentially be used.  GENECAPP is a 
new technique developed by Wu et al. which allows for the capture of proteins cross-linked to a 
specific DNA sequence via sequence-specific hybridization present on a solid support (2011). 
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This allows for a DNA-centric approach to examining proteins bound to a specific DNA 
sequence. Protein-DNA complexes are digested via exonucleases, rendering the bound DNA 
sequence single stranded and capable of binding the sequence-specific hybridization 
complementary DNA oligonucleotide array. Captured complexes associated with the p21 
promoter can thus be analysed via mass-spectrometry for present p53 PTMs and cofactors. 
Additionally, it is also possible that p21 levels increase independently of p53. To 
determine if EPO induces p21 expression independent of p53, DA3-EPOR/p53DD cells could be 
immunoblotted for p21 expression in the presence of EPO.   
5.4 Translational studies in other systems 
It is important to examine whether the observed effects of EPO treatment on apoptosis and p53 
in DA3-EPOR cells can be replicated in other systems to give support to the translatability of our 
findings. Future work could examine the effects of EPO in human cell lines that express EPOR 
in addition to other murine cell lines. A bioinformatics study could also be performed to 
determine the relative correlation between EPOR expression, WTp53 protein status, and patient 
prognosis and overall survival in clinics. Finally, the usage of mouse models would allow for 
examining the effects of EPO on tumourigenesis and the p53 network in a more physiological 
system.  
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